Arlene Chapman MD
Academic Appointment
- Professor of Medicine with Tenure, Department of Medicine, Renal Division, Emory University School of Medicine
- Professor of Medicine with Tenure, Renal Division, Emory University School of Medicine
Education
Degrees
- BS from Guelph University
- MD from McMaster University
Research
Focus
- Clinical investigation in the fields of hereditary renal diseases, autosomal dominant polycystic kidney diseases, pharmacogenetics, essential hypertension, and pregnancy.
Publications
-
Overweight Status, Obesity, and Progression to ESKD in Patients with Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 20 Page(s): 520 - 528
04/01/2025 Authors: Nowak KL; Copeland TP; Ku E; Sarnak MJ; Gitomer B; Abebe KZ; Chapman A; Perrone R; Rahbari-Oskoui FF; Steinman T -
Effect of Race on Transplantation in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 20 Page(s): 563 - 572
04/01/2025 Authors: Krishnamoorthy S; Satishchandra NG; Chapman A; McGill R -
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Kidney Int Volume: 107 Page(s): S1 - S239
02/01/2025 Authors: Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group -
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
Kidney Int Volume: 107 Page(s): 234 - 254
02/01/2025 Authors: Torres VE; Ahn C; Barten TRM; Brosnahan G; Cadnapaphornchai MA; Chapman AB; Cornec-Le Gall E; Drenth JPH; Gansevoort RT; Harris PC -
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence Program.
Kidney360 Volume: 6 Page(s): 159 - 166
01/01/2025 Authors: Hoover E; Cambareri H; Chapman AB; Chebib FT; Moore S; Perrone RD; Garimella PS -
Cardiac Localized Polycystin-2 in the Natriuretic Peptide Signaling Pathway and Hypertension.
J Am Soc Nephrol Volume: 36 Page(s): 34 - 47
01/01/2025 Authors: Mrquez-Nogueras KM; Elliott B; Thuo P; DiNello E; Knutila RM; Fritzmann GE; Vuchkovska V; Flury S; Willis M; Chapman AB -
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End-Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials.
Am J Kidney Dis Volume: 85 Page(s): 127 - 130
01/01/2025 Authors: Ku E; Copeland TP; McCulloch CE; Abebe KZ; Chonchol M; Perrone RD; Rahbari-Oskoui FF; Yu ASL; Steinman T; Chapman A -
Building a Physician/Advanced Practice Provider Partnership for Inpatient Dialysis Care.
Kidney360 Volume: 5 Page(s): 1922 - 1924
12/01/2024 Authors: McGill RL; Poma T; Chapman AB -
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers.
Clin Transl Sci Volume: 17 Page(s): e13816
05/01/2024 Authors: Mehanna M; McDonough CW; Smith SM; Gong Y; Gums JG; Chapman AB; Johnson JA; Cooper-DeHoff RM -
All Patients with ADPKD Should Undergo Screening for Intracranial Aneurysms: COMMENTARY.
Kidney360 Volume: 5 Page(s): 499 - 500
04/01/2024 Authors: Chapman AB -
Circulating microRNA Biomarkers of Thiazide Response in Hypertension.
J Am Heart Assoc Volume: 13 Page(s): e032433
02/20/2024 Authors: Chekka LMS; Tantawy M; Langaee T; Wang D; Renne R; Chapman AB; Gums JG; Boerwinkle E; Cooper-DeHoff RM; Johnson JA -
Magnetic resonance imaging preprocessing and radiomic features for classification of autosomal dominant polycystic kidney disease genotype.
J Med Imaging (Bellingham) Volume: 10 Page(s): 064503
11/01/2023 Authors: Kremer LE; Chapman AB; Armato SG -
Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation.
Kidney Int Volume: 104 Page(s): 334 - 342
08/01/2023 Authors: Gregory AV; Chebib FT; Poudyal B; Holmes HL; Yu ASL; Landsittel DP; Bae KT; Chapman AB; Frederic R-O; Mrug M -
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
Nat Med Volume: 29 Page(s): 1867 - 1876
07/01/2023 Authors: Inker LA; Collier W; Greene T; Miao S; Chaudhari J; Appel GB; Badve SV; Caravaca-Fontn F; Del Vecchio L; Floege J -
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Am J Kidney Dis Volume: 81 Page(s): 517 - 527.e1
05/01/2023 Authors: Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC -
OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD.
Kidney Int Rep Volume: 8 Page(s): 989 - 1001
05/01/2023 Authors: Perrone RD; Oberdhan D; Ouyang J; Bichet DG; Budde K; Chapman AB; Gitomer BY; Horie S; Ong ACM; Torres VE -
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
Clin J Am Soc Nephrol Volume: 18 Page(s): 183 - 192
02/01/2023 Authors: Collier W; Inker LA; Haaland B; Appel GB; Badve SV; Caravaca-Fontn F; Chalmers J; Floege J; Goicoechea M; Imai E -
Measuring copeptin, a surrogate for vasopressin in patients with hypertension - Can it identify those who are volume Responsive?
Clin Biochem Volume: 112 Page(s): 48 - 52
02/01/2023 Authors: Lobo R; Lieske JC; Donato LJ; Hickson LJ; Hodge DO; Chapman A; Schwartz GL; Jaffe AS -
Effects of Bardoxolone Methyl in Alport Syndrome.
Clin J Am Soc Nephrol Volume: 17 Page(s): 1763 - 1774
12/01/2022 Authors: Warady BA; Pergola PE; Agarwal R; Andreoli S; Appel GB; Bangalore S; Block GA; Chapman AB; Chin MP; Gibson KL -
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Clin Transl Sci Volume: 15 Page(s): 2858 - 2867
12/01/2022 Authors: Chekka LMS; Cooper-DeHoff RM; Gums JG; Chapman AB; Johnson JA -
Macromolecular Circulating Immune Complexes in IgA Nephropathy
Volume: 32 Page(s): 1031 - 1032
10/31/2022 Authors: Aryal RP; Matsumoto Y; Heimburg-Molinaro J; Park SS; Wever WJ; Lehoux S; Stavenhagen K; van JAEW; Van Die I; Chapman AB -
Identification and characterization of circulating immune complexes in IgA nephropathy.
Sci Adv Volume: 8 Page(s): eabm8783
10/28/2022 Authors: Matsumoto Y; Aryal RP; Heimburg-Molinaro J; Park SS; Wever WJ; Lehoux S; Stavenhagen K; van Wijk JAE; Van Die I; Chapman AB -
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.
Kidney Med Volume: 4 Page(s): 100538
10/01/2022 Authors: Perrone RD; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC -
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.
Metabolites Volume: 12
08/24/2022 Authors: Mehanna M; McDonough CW; Smith SM; Gong Y; Gums JG; Chapman AB; Johnson JA; Cooper-DeHoff RM -
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States.
Clin J Am Soc Nephrol Volume: 17 Page(s): 976 - 985
07/01/2022 Authors: McGill RL; Saunders MR; Hayward AL; Chapman AB -
Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
Am J Kidney Dis Volume: 79 Page(s): 677 - 687.e1
05/01/2022 Authors: Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J -
Emerging Role of Clinical Genetics in CKD.
Kidney Med Volume: 4 Page(s): 100435
04/01/2022 Authors: Devarajan P; Chertow GM; Susztak K; Levin A; Agarwal R; Stenvinkel P; Chapman AB; Warady BA -
Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 17 Page(s): 374 - 384
03/01/2022 Authors: Bae KT; Tao C; Feldman R; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE -
Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.
Kidney360 Volume: 3 Page(s): 307 - 316
02/01/2022 Authors: Eadon MT; Maddatu J; Moe SM; Sinha AD; Ferreira RM; Miller BW; Sher SJ; Su J; Pratt VM; Chapman AB -
Utilization of Cystatin C in the Outpatient Setting.
Am J Nephrol Volume: 53 Page(s): 534 - 541
01/01/2022 Authors: Torres J; Ennis JL; Chapman AB; McGill RL -
PKD1 Compared With PK D2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies.
Kidney Int Rep Volume: 7 Page(s): 117 - 120
01/01/2022 Authors: Steele C; You Z; Gitomer BY; Brosnahan GM; Abebe KZ; Braun WE; Chapman AB; Harris PC; Perrone RD; Steinman TI -
Agreement of Food Records and 24-Hour Urine Studies in Clinical Practice.
J Ren Nutr Volume: 32 Page(s): 51 - 57
01/01/2022 Authors: Betz MV; Coe FL; Chapman AB -
Polycystic Kidney Disease in the Real World.
Kidney360 Volume: 2 Page(s): 1882 - 1883
12/30/2021 Authors: Chapman AB; McGill R -
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites Volume: 11
09/21/2021 Authors: Mehanna M; McDonough CW; Smith SM; Gong Y; Gums JG; Chapman AB; Johnson JA; McIntyre L; Cooper-DeHoff RM -
Tolvaptan in ADPKD Patients With Very Low Kidney Function.
Kidney Int Rep Volume: 6 Page(s): 2171 - 2178
08/01/2021 Authors: Torres VE; Gansevoort RT; Perrone RD; Chapman AB; Ouyang J; Lee J; Japes H; Nourbakhsh A; Wang T -
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
Am J Med Volume: 134 Page(s): 918 - 925.e2
07/01/2021 Authors: Chekka LMS; Chapman AB; Gums JG; Cooper-DeHoff RM; Johnson JA -
The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial.
J Am Soc Nephrol Volume: 32 Page(s): 1801 - 1812
07/01/2021 Authors: Heida JE; Gansevoort RT; Torres VE; Devuyst O; Perrone RD; Lee J; Li H; Ouyang J; Chapman AB -
Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep Volume: 6 Page(s): 953 - 961
04/01/2021 Authors: El Ters M; Lu P; Mahnken JD; Stubbs JR; Zhang S; Wallace DP; Grantham JJ; Chapman AB; Torres VE; Harris PC -
Mineral bone disease in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 99 Page(s): 977 - 985
04/01/2021 Authors: Gitomer B; Pereira R; Salusky IB; Stoneback JW; Isakova T; Cai X; Dalrymple LS; Ofsthun N; You Z; Malluche HH -
METABOLOMICS REVEALS RACIAL DIFFERENCE IN BLOOD PRESSURE RESPONSE TO METOPROLOL.
Volume: 109 Page(s): S23 - S24
03/01/2021 Authors: Mehanna M; Gong Y; McDonough C; Gums JG; Chapman AB; Turner ST; Johnson J; Cooper-DeHoff R -
Advancing Nephrology: Division Leaders Advise ASN.
Clin J Am Soc Nephrol Volume: 16 Page(s): 319 - 327
02/08/2021 Authors: Braden GL; Chapman A; Ellison DH; Gadegbeku CA; Gurley SB; Igarashi P; Kelepouris E; Moxey-Mims MM; Okusa MD; Plumb TJ -
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop.
Am J Kidney Dis Volume: 77 Page(s): 255 - 263
02/01/2021 Authors: Cho Y; Tong A; Craig JC; Mustafa RA; Chapman A; Perrone RD; Ahn C; Fowler K; Torres V; Gansevoort RT -
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
Am J Nephrol Volume: 52 Page(s): 180 - 189
01/01/2021 Authors: Chertow GM; Appel GB; Andreoli S; Bangalore S; Block GA; Chapman AB; Chin MP; Gibson KL; Goldsberry A; Iijima K -
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies.
Kidney Med Volume: 3 Page(s): 536 - 545.e1
01/01/2021 Authors: Nowak KL; Murray K; You Z; Gitomer B; Brosnahan G; Abebe KZ; Braun W; Chapman A; Harris PC; Miskulin D -
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review.
PLoS One Volume: 16 Page(s): e0252479
01/01/2021 Authors: Natale P; Hannan E; Sautenet B; Ju A; Perrone RD; Burnette E; Casteleijn N; Chapman A; Eastty S; Gansevoort R -
Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass.
Am J Nephrol Volume: 52 Page(s): 173 - 176
01/01/2021 Authors: Prochaska M; Asplin J; Chapman A; Worcester E -
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 16 Page(s): 48 - 58
12/31/2020 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O -
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations (vol 5, pg 801, 2020)
KIDNEY INTERNATIONAL REPORTS Volume: 5 Page(s): 2407 - +
12/01/2020 Authors: Perrone RD; Chapman AB; Oberdhan D -
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT Pharmacometrics Syst Pharmacol Volume: 9 Page(s): 678 - 685
12/01/2020 Authors: Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF -
Plasma Microrna Profiling Reveals Potential Biomarkers of Thiazide Response
Volume: 142
11/17/2020 Authors: Chekka LMS; Langaee TY; Wang D; Rolf R; Chapman AB; Gums J; Turner ST; Cooper-Dehoff RM; Johnson JA -
'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study.
BMJ Open Volume: 10 Page(s): e038005
10/10/2020 Authors: Logeman C; Cho Y; Sautenet B; Rangan GK; Gutman T; Craig J; Ong A; Chapman A; Ahn C; Coolican H -
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey.
Am J Kidney Dis Volume: 76 Page(s): 361 - 373
09/01/2020 Authors: Cho Y; Rangan G; Logeman C; Ryu H; Sautenet B; Perrone RD; Nadeau-Fredette A-C; Mustafa RA; Htay H; Chonchol M -
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
JCI Insight Volume: 5
08/06/2020 Authors: Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF -
Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review.
Am J Kidney Dis Volume: 76 Page(s): 213 - 223
08/01/2020 Authors: Sautenet B; Cho Y; Gutman T; Rangan G; Ong A; Chapman AB; Ahn C; Coolican H; Tze-Wah Kao J; Fowler K -
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.
Kidney360 Volume: 1 Page(s): 648 - 656
07/01/2020 Authors: Grau L; Gitomer B; McNair B; Wolf M; Harris P; Brosnahan G; Torres V; Steinman T; Yu A; Chapman A -
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol Volume: 31 Page(s): 1640 - 1651
07/01/2020 Authors: Bae KT; Shi T; Tao C; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE -
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.
Kidney Int Rep Volume: 5 Page(s): 801 - 812
06/01/2020 Authors: Perrone RD; Chapman AB; Oberdhan D; Czerwiec FS; Sergeyeva O; Ouyang J; Shoaf SE -
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.
Kidney Int Rep Volume: 5 Page(s): 790 - 800
06/01/2020 Authors: Perrone RD; Chapman AB; Oberdhan D; Czerwiec FS; Sergeyeva O; Ouyang J; Shoaf SE -
Sorting nexin 1 loss results in increased oxidative stress and hypertension.
FASEB J Volume: 34 Page(s): 7941 - 7957
06/01/2020 Authors: Yang J; Asico LD; Beitelshees AL; Feranil JB; Wang X; Jones JE; Armando I; Cuevas SG; Schwartz GL; Gums JG -
Polycystins, ADPKD, and Cardiovascular Disease.
Kidney Int Rep Volume: 5 Page(s): 396 - 406
04/01/2020 Authors: Kuo IY; Chapman AB -
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
Am J Hypertens Volume: 33 Page(s): e2
02/22/2020 Authors: Mehanna M; Wang Z; Gong Y; McDonough CW; Beitelshees AL; Gums JG; Chapman AB; Schwartz GL; Bailey KR; Johnson JA -
Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 97 Page(s): 370 - 382
02/01/2020 Authors: Hopp K; Cornec-Le Gall E; Senum SR; Te Paske IBAW; Raj S; Lavu S; Baheti S; Edwards ME; Madsen CD; Heyer CM -
Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients.
Kidney Int Rep Volume: 4 Page(s): 1742 - 1748
12/01/2019 Authors: Hanudel MR; Salusky IB; Pereira RC; Wang W; You Z; Nowak KL; Brosnahan GM; Torres VE; Chapman AB; Perrone RD -
Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study.
Nephrology (Carlton) Volume: 24 Page(s): 1214 - 1224
12/01/2019 Authors: Cho Y; Sautenet B; Gutman T; Rangan G; Craig JC; Ong AC; Chapman A; Ahn C; Coolican H; Kao JT-W -
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Sci Rep Volume: 9 Page(s): 17323
11/21/2019 Authors: Singh S; McDonough CW; Gong Y; Bailey KR; Boerwinkle E; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM; Johnson JA -
Real-World Associations Between Renin-Angiotensin-Aldosterone System Inhibition Therapy, Hyperkalemia, and Outcomes: A Clinical and Scientific Call to Action.
J Am Heart Assoc Volume: 8 Page(s): e014845
11/19/2019 Authors: Chapman A; Gunning S -
A Practical Approach to Polycystic Liver Disease.
Clin Liver Dis (Hoboken) Volume: 14 Page(s): 176 - 179
11/01/2019 Authors: Patel A; Chapman AB; Mikolajczyk AE -
2 -Adrenergic Receptor Gene Affects the Heart Rate Response of -Blockers: Evidence From 3 Clinical Studies.
J Clin Pharmacol Volume: 59 Page(s): 1462 - 1470
11/01/2019 Authors: Shahin MH; Rouby NE; Conrado DJ; Gonzalez D; Gong Y; Lobmeyer MT; Beitelshees AL; Boerwinkle E; Gums JG; Chapman A -
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clin Transl Sci Volume: 12 Page(s): 497 - 504
09/01/2019 Authors: Singh S; El Rouby N; McDonough CW; Gong Y; Bailey KR; Boerwinkle E; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM -
Genome-Wide Meta-Analysis of Blood Pressure Response to 1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
J Am Heart Assoc Volume: 8 Page(s): e013115
08/20/2019 Authors: Singh S; Warren HR; Hiltunen TP; McDonough CW; El Rouby N; Salvi E; Wang Z; Garofalidou T; Fyhrquist F; Kontula KK -
Intracranial Aneurysms in ADPKD: How Far Have We Come?
Clin J Am Soc Nephrol Volume: 14 Page(s): 1119 - 1121
08/01/2019 Authors: Kuo IY; Chapman A -
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 96 Page(s): 159 - 169
07/01/2019 Authors: Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K -
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Am J Hypertens Volume: 32 Page(s): 668 - 675
06/11/2019 Authors: Mehanna M; Wang Z; Gong Y; McDonough CW; Beitelshees AL; Gums JG; Chapman AB; Schwartz GL; Bailey KR; Johnson JA -
Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 14 Page(s): 823 - 833
06/07/2019 Authors: Bae KT; Zhou W; Shen C; Landsittel DP; Wu Z; Tao C; Chapman AB; Torres VE; Yu ASL; Mrug M -
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
Kidney Int Volume: 95 Page(s): 1253 - 1261
05/01/2019 Authors: Yu ASL; Shen C; Landsittel DP; Grantham JJ; Cook LT; Torres VE; Chapman AB; Bae KT; Mrug M; Harris PC -
Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.
Complement Ther Med Volume: 43 Page(s): 157 - 164
04/01/2019 Authors: Rahbari-Oskoui FF; Abramson JL; Bruckman AM; Chapman AB; Cotsonis GA; Johnson SA; Bliwise DL -
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
Eur J Pharm Sci Volume: 131 Page(s): 93 - 98
04/01/2019 Authors: Solayman MH; Langaee TY; Gong Y; Shahin MH; Turner ST; Chapman AB; Gums JG; Boerwinkle E; Beitelshees AL; El-Hamamsy M -
GENOME WIDE META-ANALYSIS OF BLOOD PRESSURE RESPONSE TO B-BLOCKERS: RESULTS FROM INTERNATIONAL CONSORTIUNI OF ANTIHYPERTENSIVE PHARMACOGENOMICS STUDIES.
Volume: 105 Page(s): S27 - S27
03/01/2019 Authors: Singh S; Warren HR; Hiltunen TP; Salvi E; El Rouby N; Garofalidou T; Fyhrquist F; Kontula KK; Glorioso V; Zaninello R -
EXPLORATION OF HEPATOTOXICITY POTENTIAL AND ITS PLAUSIBLE MECHANISM OF SPECIFIC PROGESTERONE-RECEPTOR MODULATORS.
Volume: 105 Page(s): S111 - S112
03/01/2019 Authors: Singh S; El Rouby N; McDonough CW; Gong Y; Bailey KR; Beitelshees AL; Boerwinkle E; Chapman AB; Gums JG; Turner ST -
SYSTEMATIC, HYPOTHESIS-DRIVEN APPROACH TO IDENTIFY CIRCULATING MICRORNAS THAT PREDICT BLOOD PRESSURE RESPONSE TO ANTIHYPERTENSIVE DRUGS.
Volume: 105 Page(s): S18 - S18
03/01/2019 Authors: Chekka LMS; Singh S; Langaee TY; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM; Johnson JA -
SYSTEMATIC, HYPOTHESIS-DRIVEN APPROACH TO IDENTIFY CIRCULATING MICRORNAS THAT PREDICT BLOOD PRESSURE RESPONSE TO ANTIHYPERTENSIVE DRUGS.
Volume: 105 Page(s): S89 - S89
03/01/2019 Authors: Chekka LMS; Singh S; Langaee TY; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM; Johnson JA -
GENOME WIDE META-ANALYSIS OF BLOOD PRESSURE RESPONSE TO B-BLOCKERS: RESULTS FROM INTERNATIONAL CONSORTIUM OF ANTIHYPERTENSIVE PHARMACOGENOMICS STUDIES.
Volume: 105 Page(s): S80 - S80
03/01/2019 Authors: Singh S; Warren HR; Hiltunen TP; Salvi E; El Rouby N; Garofalidou T; Fyhrquist F; Kontula KK; Glorioso V; Zaninello R -
GENOME WIDE META-ANALYSIS OF BLOOD PRESSURE RESPONSE TO B-BLOCKERS: RESULTS FROM INTERNATIONAL CONSORTIUM OF ANTIHYPERTENSIVE PHARMACOGENOMICS STUDIES.
Volume: 105 Page(s): S16 - S16
03/01/2019 Authors: Singh S; Warren HR; Hiltunen TP; Salvi E; El Rouby N; Garofalidou T; Fyhrquist F; Kontula KK; Glorioso V; Zaninello R -
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
BMC Nephrol Volume: 20 Page(s): 66
02/25/2019 Authors: Kim K; Trott JF; Gao G; Chapman A; Weiss RH -
The future of pharmacogenetics in the treatment of hypertension.
Pharmacogenomics Volume: 20 Page(s): 129 - 132
02/01/2019 Authors: Cunningham PN; Chapman AB -
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.
Pharmacogenet Genomics Volume: 29 Page(s): 18 - 22
01/01/2019 Authors: Collins KS; Pratt VM; Stansberry WM; Medeiros EB; Kannegolla K; Swart M; Skaar TC; Chapman AB; Decker BS; Moorthi RN -
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
PLoS One Volume: 14 Page(s): e0221957
01/01/2019 Authors: Cunningham PN; Wang Z; Grove ML; Cooper-DeHoff RM; Beitelshees AL; Gong Y; Gums JG; Johnson JA; Turner ST; Boerwinkle E -
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
BMC Nephrol Volume: 19 Page(s): 378
12/27/2018 Authors: McKenzie KA; El Ters M; Torres VE; Harris PC; Chapman AB; Mrug M; Rahbari-Oskoui FF; Bae KT; Landsittel DP; Bennett WM -
Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.
Kidney Int Volume: 94 Page(s): 1053 - 1068
12/01/2018 Authors: Tong A; Manns B; Wang AYM; Hemmelgarn B; Wheeler DC; Gill J; Tugwell P; Pecoits-Filho R; Crowe S; Harris T -
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Volume: 28 Page(s): 251 - 255
11/01/2018 Authors: Singh S; Wang Z; Shahin MH; Langaee TY; Gong Y; Turner ST; Chapman AB; Gums JG; McDonough CW; Bailey KR -
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
J Am Soc Nephrol Volume: 29 Page(s): 2458 - 2470
10/01/2018 Authors: Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL -
The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.
Am J Kidney Dis Volume: 72 Page(s): 302 - 308
08/01/2018 Authors: Cornec-Le Gall E; Chebib FT; Madsen CD; Senum SR; Heyer CM; Lanpher BC; Patterson MC; Albright RC; Yu AS; Torres VE -
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC Med Genomics Volume: 11 Page(s): 55
06/20/2018 Authors: S ACC; Webb A; Gong Y; McDonough CW; Shahin MH; Datta S; Langaee TY; Turner ST; Beitelshees AL; Chapman AB -
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep Volume: 3 Page(s): 619 - 624
05/01/2018 Authors: Dad T; Abebe KZ; Bae KT; Comer D; Torres VE; Czarnecki PG; Schrier RW; Steinman TI; Moore CG; Chapman AB -
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Am J Kidney Dis Volume: 71 Page(s): 666 - 676
05/01/2018 Authors: Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF -
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circ Genom Precis Med Volume: 11 Page(s): e001854
04/01/2018 Authors: McDonough CW; Magvanjav O; S ACC; El Rouby NM; Dave C; Deitchman AN; Kawaguchi-Suzuki M; Mei W; Shen Y; Singh RSP -
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Nephrol Dial Transplant Volume: 33 Page(s): 645 - 652
04/01/2018 Authors: Cornec-Le Gall E; Blais JD; Irazabal MV; Devuyst O; Gansevoort RT; Perrone RD; Chapman AB; Czerwiec FS; Ouyang J; Heyer CM -
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
J Am Heart Assoc Volume: 7
03/09/2018 Authors: Singh S; McDonough CW; Gong Y; Alghamdi WA; Arwood MJ; Bargal SA; Dumeny L; Li W-Y; Mehanna M; Stockard B -
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant Volume: 33 Page(s): 477 - 489
03/01/2018 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Dandurand A; Ouyang J; Czerwiec FS; Blais JD; TEMPO 4:4 Trial Investigators -
GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL PHARMACOGENETIC VARIANTS ASSOCIATED WITH CHLORTHALIDONE BLOOD PRESSURE RESPONSE IN AFRICAN AMERICANS.
Volume: 103 Page(s): S50 - S50
03/01/2018 Authors: Singh S; Gong Y; McDonough CW; Bailey KR; Beitelshees AL; Boerwinkle E; Chapman AB; Gums JG; Turner ST; Cooper-DeHoff RM -
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Volume: 93 Page(s): 691 - 699
03/01/2018 Authors: Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF -
Protein kinase C deletion causes hypotension and decreased vascular contractility.
J Hypertens Volume: 36 Page(s): 510 - 519
03/01/2018 Authors: Wynne BM; McCarthy CG; Szasz T; Molina PA; Chapman AB; Webb RC; Klein JD; Hoover RS -
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to -Blockers.
J Am Heart Assoc Volume: 7
02/24/2018 Authors: Shahin MH; Conrado DJ; Gonzalez D; Gong Y; Lobmeyer MT; Beitelshees AL; Boerwinkle E; Gums JG; Chapman A; Turner ST -
ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.
Am J Kidney Dis Volume: 71 Page(s): 294 - 296
02/01/2018 Authors: Braun WE; Abebe KZ; Brosnahan G; Patterson CG; Chapman AB; Harris PC; Hogan MC; Perrone RD; Torres VE; Miskulin DC -
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.
Am J Kidney Dis Volume: 71 Page(s): 225 - 235
02/01/2018 Authors: Oberdhan D; Cole JC; Krasa HB; Cheng R; Czerwiec FS; Hays RD; Chapman AB; Perrone RD -
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol Volume: 29 Page(s): 571 - 578
02/01/2018 Authors: Nowak KL; You Z; Gitomer B; Brosnahan G; Torres VE; Chapman AB; Perrone RD; Steinman TI; Abebe KZ; Rahbari-Oskoui FF -
Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.
Expert Rev Precis Med Drug Dev Volume: 3 Page(s): 33 - 47
01/01/2018 Authors: Eadon MT; Kanuri SH; Chapman AB -
Hypoxia-Inducible Factor 1 (HIF-1), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease.
Am J Nephrol Volume: 47 Page(s): 228 - 230
01/01/2018 Authors: Rahbari-Oskoui FF; Chapman AB -
Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Curr Hypertens Rev Volume: 14 Page(s): 39 - 47
01/01/2018 Authors: Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD -
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
J Am Heart Assoc Volume: 7
12/29/2017 Authors: Shahin MH; Gong Y; Frye RF; Rotroff DM; Beitelshees AL; Baillie RA; Chapman AB; Gums JG; Turner ST; Boerwinkle E -
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
J Clin Hypertens (Greenwich) Volume: 19 Page(s): 1301 - 1308
12/01/2017 Authors: Mehanna M; Gong Y; McDonough CW; Beitelshees AL; Gums JG; Chapman AB; Schwartz GL; Johnson JA; Turner ST; Cooper-DeHoff RM -
New treatment paradigms for ADPKD: moving towards precision medicine.
Nat Rev Nephrol Volume: 13 Page(s): 750 - 768
12/01/2017 Authors: Lanktree MB; Chapman AB -
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
Trials Volume: 18 Page(s): 560
11/23/2017 Authors: Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT-W -
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Sci Rep Volume: 7 Page(s): 16068
11/25/2017 Authors: S ACC; Webb A; Gong Y; McDonough CW; Datta S; Langaee TY; Turner ST; Beitelshees AL; Chapman AB; Boerwinkle E -
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
N Engl J Med Volume: 377 Page(s): 1930 - 1942
11/16/2017 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS -
Autosomal dominant polycystic kidney disease.
CMAJ Volume: 189 Page(s): E1396
11/13/2017 Authors: Lanktree MB; Chapman AB -
Genetic Variants Associated With Uncontrolled Blood Pressure onThiazide Diuretic/-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)and INVEST (International Verapamil-SR Trandolapril Study) Trials.
J Am Heart Assoc Volume: 6
11/02/2017 Authors: Magvanjav O; Gong Y; McDonough CW; Chapman AB; Turner ST; Gums JG; Bailey KR; Boerwinkle E; Beitelshees AL; Tanaka T -
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
Kidney Int Rep Volume: 2 Page(s): 1132 - 1140
11/01/2017 Authors: Devuyst O; Chapman AB; Shoaf SE; Czerwiec FS; Blais JD -
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
Nephrol Dial Transplant Volume: 32 Page(s): 1857 - 1865
11/01/2017 Authors: Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC -
Image texture features predict renal function decline in patients with autosomal dominantpolycystic kidney disease.
Kidney Int Volume: 92 Page(s): 1206 - 1216
11/01/2017 Authors: Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM -
A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 12 Page(s): 1695 - 1698
10/06/2017 Authors: Reddy BV; Chapman AB -
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 12 Page(s): 1461 - 1469
09/07/2017 Authors: Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ -
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
J Clin Pharmacol Volume: 57 Page(s): 906 - 917
07/01/2017 Authors: Shoaf SE; Chapman AB; Torres VE; Ouyang J; Czerwiec FS -
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Nephrol Dial Transplant Volume: 32 Page(s): 1262
07/01/2017 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Dandurand A; Ouyang J; Czerwiec FS; Blais JD; TEMPO 4:4 Trial Investigators -
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
Nephrol Dial Transplant Volume: 32 Page(s): 969 - 975
06/01/2017 Authors: Grantham JJ; Chapman AB; Blais J; Czerwiec FS; Devuyst O; Gansevoort RT; Higashihara E; Krasa H; Zhou W; Ouyang J -
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
J Am Soc Nephrol Volume: 28 Page(s): 1592 - 1602
05/01/2017 Authors: Devuyst O; Chapman AB; Gansevoort RT; Higashihara E; Perrone RD; Torres VE; Blais JD; Zhou W; Ouyang J; Czerwiec FS -
Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease inPatients With Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep Volume: 2 Page(s): 442 - 450
05/01/2017 Authors: Perrone RD; Mouksassi M-S; Romero K; Czerwiec FS; Chapman AB; Gitomer BY; Torres VE; Miskulin DC; Broadbent S; Marier JF -
A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.
Kidney Int Rep Volume: 2 Page(s): 451 - 460
05/01/2017 Authors: Perrone RD; Mouksassi M-S; Romero K; Czerwiec FS; Chapman AB; Gitomer BY; Torres VE; Miskulin DC; Broadbent S; Marier JF -
ANNUAL RATE OF GROWTH IN TOTAL LIVER AND KIDNEY VOLUME IS A NOVEL PARAMETER WHEN ASSESSING SYMPTOM BURDEN FROM LIVER CYSTS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Volume: 152 Page(s): S1155 - S1156
04/01/2017 Authors: Mikolajczyk AE; Gao G; Chapman AB -
Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.
Am J Kidney Dis Volume: 69 Page(s): 482 - 484
03/01/2017 Authors: Shen C; Landsittel D; Irazabal MV; Yu ASL; Chapman AB; Mrug M; Grantham JJ; Bae KT; Bennett WM; Flessner MF -
Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.
Nephrol Dial Transplant Volume: 32 Page(s): 487 - 497
03/01/2017 Authors: Pejchinovski M; Siwy J; Metzger J; Dakna M; Mischak H; Klein J; Jankowski V; Bae KT; Chapman AB; Kistler AD -
ASSOCIATION OF ADRB1 GENE DNA METHYLATION WITH ANTIHYPERTENSIVE RESPONSE TO METOPROLOL IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES 2 (PEAR-2) STUDY.
Volume: 101 Page(s): S47 - S47
02/01/2017 Authors: Solayman MH; Langaee TY; Gong Y; Turner ST; Chapman AB; Gums JG; Boerwinkle E; Beitelshees AL; El-Wakeel L; El-Hamamsy M -
RNA-SEQ ANALYSES IDENTIFY MOLECULAR MARKERS OF BLOOD PRESSURE (BP) RESPONSE TO THIAZIDE DIURETICS (TD)
Volume: 101 Page(s): S95 - S95
02/01/2017 Authors: Sa AC; Webb A; Gong Y; McDonough CW; Shahin MH; Datta S; Langaee TY; Turner ST; Beitelshees AL; Chapman AB -
RNA-SEQ ANALYSES IDENTIFY MOLECULAR MARKERS OF BLOOD PRESSURE (BP) RESPONSE TO THIAZIDE DIURETICS (TD)
Volume: 101 Page(s): S12 - S12
02/01/2017 Authors: Sa AC; Webb A; Gong Y; McDonough CW; Shahin MH; Datta S; Langaee TY; Turner ST; Beitelshees AL; Chapman AB -
A GENOME WIDE ASSOCIATION STUDY IDENTIFIES PHARMACOGENOMIC VARIANTS ASSOCIATED WITH CHLORTHALIDONE INDUCED GLUCOSE CHANGE IN AFRICAN AMERICANS
Volume: 101 Page(s): S9 - S9
02/01/2017 Authors: Singh S; Alghamdi W; Arwood MJ; Bargal SA; de Oliveira F; Dumeny L; Wen-Yi L; Mehanna M; Stockard B; Yang G -
THIAZIDE INDUCED HYPERURICEMIA: NOVEL INSIGHTS FROM METABOLOMICS AND GENOMICS INTEGRATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES 2 (PEAR 2) STUDY
Volume: 101 Page(s): S13 - S13
02/01/2017 Authors: Shahin MH; Michailidis G; Gong Y; Beitelshees AL; Chapman AB; Gums JG; Boerwinkle E; Turner ST; Cooper-DeHoff RM; Johnson JA -
THIAZIDE INDUCED HYPERURICEMIA: NOVEL INSIGHTS FROM METABOLOMICS AND GENOMICS INTEGRATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES 2 (PEAR 2) STUDY.
Volume: 101 Page(s): S46 - S46
02/01/2017 Authors: Shahin MH; Michailidis G; Gong Y; Beitelshees AL; Chapman AB; Gums JG; Boerwinkle E; Turner ST; Cooper-DeHoff RM; Johnson JA -
Dietary salt restriction is beneficial to the management of autosomal dominant polycystickidney disease.
Kidney Int Volume: 91 Page(s): 493 - 500
02/01/2017 Authors: Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC -
Tolvaptan and Kidney Pain in Patients With Autosomal DominantPolycystic Kidney Disease: Secondary Analysis Froma Randomized Controlled Trial.
Am J Kidney Dis Volume: 69 Page(s): 210 - 219
02/01/2017 Authors: Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE -
Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Curr Hypertens Rev Volume: 13 Page(s): 109 - 120
01/01/2017 Authors: Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC -
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Am J Nephrol Volume: 45 Page(s): 257 - 266
01/01/2017 Authors: Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O; REPRISE Trial Investigators -
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
Circ Cardiovasc Genet Volume: 10
01/01/2017 Authors: Shahin MH; S AC; Webb A; Gong Y; Langaee T; McDonough CW; Riva A; Beitleshees AL; Chapman AB; Gums JG -
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Hypertension Volume: 69 Page(s): 51 - 59
01/01/2017 Authors: Salvi E; Wang Z; Rizzi F; Gong Y; McDonough CW; Padmanabhan S; Hiltunen TP; Lanzani C; Zaninello R; Chittani M -
Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease.
Clin Gastroenterol Hepatol Volume: 15 Page(s): 17 - 24
01/01/2017 Authors: Mikolajczyk AE; Te HS; Chapman AB -
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.
Pediatr Nephrol Volume: 32 Page(s): 31 - 42
01/01/2017 Authors: Reddy BV; Chapman AB -
The role of plasma renin activity for improving precision of antihypertensive drug therapy in European Americans and African Americans
Volume: 36 Page(s): E214 - E214
12/01/2016 Authors: Mehanna M; Gong Y; McDonough CW; Beitelshees A; Gums J; Chapman AB; Johnson J; Turner S; Cooper-DeHoff R -
Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease.
Phys Med Biol Volume: 61 Page(s): 7864 - 7880
11/21/2016 Authors: Kim Y; Bae SK; Cheng T; Tao C; Ge Y; Chapman AB; Torres VE; Yu ASL; Mrug M; Bennett WM -
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Kidney Int Rep Volume: 1 Page(s): 213 - 220
11/01/2016 Authors: Irazabal MV; Blais JD; Perrone RD; Gansevoort RT; Chapman AB; Devuyst O; Higashihara E; Harris PC; Zhou W; Ouyang J -
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Nephrol Dial Transplant Volume: 31 Page(s): 1887 - 1894
11/01/2016 Authors: Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD -
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
Am J Hypertens Volume: 29 Page(s): 1186 - 1194
10/01/2016 Authors: Gharaibeh KA; Turner ST; Hamadah AM; Chapman AB; Cooper-Dehoff RM; Johnson JA; Gums JG; Bailey KR; Schwartz GL -
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension Volume: 68 Page(s): 621 - 629
09/01/2016 Authors: Shahin MH; Gong Y; McDonough CW; Rotroff DM; Beitelshees AL; Garrett TJ; Gums JG; Motsinger-Reif A; Chapman AB; Turner ST -
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol Volume: 27 Page(s): 2872 - 2884
09/01/2016 Authors: Heyer CM; Sundsbak JL; Abebe KZ; Chapman AB; Torres VE; Grantham JJ; Bae KT; Schrier RW; Perrone RD; Braun WE -
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics Volume: 12
08/01/2016 Authors: de Oliveira FA; Shahin MH; Gong Y; McDonough CW; Beitelshees AL; Gums JG; Chapman AB; Boerwinkle E; Turner ST; Frye RF -
Mutations in GANAB, Encoding the Glucosidase II Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Am J Hum Genet Volume: 98 Page(s): 1193 - 1207
06/02/2016 Authors: Porath B; Gainullin VG; Cornec-Le Gall E; Dillinger EK; Heyer CM; Hopp K; Edwards ME; Madsen CD; Mauritz SR; Banks CJ -
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Clin J Am Soc Nephrol Volume: 11 Page(s): 803 - 811
05/06/2016 Authors: Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS -
URINE PEPTIDE MARKERS PREDICTS ESRD RISK IN ADPKD AND REVEAL PROTEOLYTIC PATWAYS INVOLVED IN PROGRESSION
Volume: 31 Page(s): 22 - 22
05/01/2016 Authors: Pejchinovski M; Siwy J; Metzger J; Mischak H; Jankowski V; Chapman AB; Kistler AD -
URINE PROTEOME ANALYSIS OF ADPKD PATIENTS SELECTED BY A TKV IMAGING CLASSIFICATION METHOD
Volume: 31 Page(s): 95 - 95
05/01/2016 Authors: Pejchinovski M; Mischak H; Chapman AB; Kistler AD -
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol Volume: 11 Page(s): 576 - 584
04/07/2016 Authors: Kim Y; Ge Y; Tao C; Zhu J; Chapman AB; Torres VE; Yu ASL; Mrug M; Bennett WM; Flessner MF -
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Clin Transl Sci Volume: 9 Page(s): 114 - 122
04/01/2016 Authors: Chang SW; Gong Y; McDonough CW; Langaee TY; Nasiri Kenari N; Beitelshees AL; Gums JG; Chapman AB; Turner ST; Johnson JA -
A Physiologic Approach to the Pharmacogenomics of Hypertension.
Adv Chronic Kidney Dis Volume: 23 Page(s): 91 - 105
03/01/2016 Authors: Eadon MT; Chapman AB -
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to -Blockers in Hypertensive African Americans.
Hypertension Volume: 67 Page(s): 556 - 563
03/01/2016 Authors: Gong Y; Wang Z; Beitelshees AL; McDonough CW; Langaee TY; Hall K; Schmidt SOF; Curry RW; Gums JG; Bailey KR -
HYPERTENSION (HTN)/BLOOD PRESSURE (BP) SIGNATURE GENES AND BP RESPONSE TO THIAZIDE DIURETICS (TD): RESULTS FROM PEAR AND PEAR-2 STUDIES.
Volume: 99 Page(s): S19 - S19
02/01/2016 Authors: Sa AC; Webb A; Gong Y; McDonough CW; Shahin MH; Langaee TY; Turner ST; Beitelshees AL; Chapman AB; Boerwinkle E -
FINDING A NEEDLE IN THE HAYSTACK FOR THIAZIDE DIURETIC RESPONSE USING GENOMICS/TRANSCRIPTOMICS IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENIVE RESPONSES (PEAR) STUDY.
Volume: 99 Page(s): S19 - S19
02/01/2016 Authors: Shahin MH; Sa AC; Webb A; Gong Y; Langaee T; McDonough CW; Riva A; Beitelshees AL; Chapman AB; Gums JG -
HYPERTENSION (HTN)/BLOOD PRESSURE (BP) SIGNATURE GENES AND BP RESPONSE TO THIAZIDE DIURETICS (TD): RESULTS FROM PEAR AND PEAR-2 STUDIES
Volume: 99 Page(s): S31 - S32
02/01/2016 Authors: Sa AC; Webb A; Gong Y; McDonough CW; Shahin MH; Langaee TY; Turner ST; Beitelshees AL; Chapman AB; Boerwinkle E -
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions.
Am J Nephrol Volume: 44 Page(s): 130 - 140
01/01/2016 Authors: Rocco MV; Chapman A; Chertow GM; Cohen D; Chen J; Cutler JA; Diamond MJ; Freedman BI; Hawfield A; Judd E -
International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection.
Nephron Volume: 134 Page(s): 205 - 214
01/01/2016 Authors: Lantinga MA; Darding AJM; de Svaux RGL; Alam A; Bleeker-Rovers CP; Bobot M; Cornec-Le Gall E; Gevers TJG; Hassoun Z; Meijer E -
Integrating Metabolomics and Genomics Uncovers Novel Pathways and Genetic Signatures Influencing Hydrochlorothiazide Blood Pressure Response: A Genetic Response Score for Hydrochlorothiazide Use
Volume: 132
11/10/2015 Authors: Shahin MH; Rotroff DM; Webb A; Gong Y; Langaee T; McDonough CW; Beitelshees AL; Garrett T; Gums JG; Motsinger-Reif A -
Genomics-metabolomics Integrative Approach Reveals Novel Biomarkers In DPYS Associated With Higher Glucose Change After Treatment With Atenolol
Volume: 132
11/10/2015 Authors: de Oliveira FA; Shahin MH; Gong Y; McDonough CW; Beitelshees AL; Gums JG; Chapman AB; Boerwinkle E; Turner ST; Frye RF -
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
J Hypertens Volume: 33 Page(s): 2278 - 2285
11/01/2015 Authors: Gong Y; McDonough CW; Beitelshees AL; El Rouby N; Hiltunen TP; O'Connell JR; Padmanabhan S; Langaee TY; Hall K; Schmidt SOF -
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
Am J Kidney Dis Volume: 66 Page(s): 583 - 590
10/01/2015 Authors: Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S -
Closeout of the HALT-PKD trials.
Contemp Clin Trials Volume: 44 Page(s): 48 - 55
09/01/2015 Authors: Moore CG; Spillane S; Simon G; Maxwell B; Rahbari-Oskoui FF; Braun WE; Chapman AB; Schrier RW; Torres VE; Perrone RD -
Promoters of Human Cosmc and T-synthase Genes Are Similar in Structure, Yet Different in Epigenetic Regulation.
J Biol Chem Volume: 290 Page(s): 19018 - 19033
07/31/2015 Authors: Zeng J; Mi R; Wang Y; Li Y; Lin L; Yao B; Song L; van Die I; Chapman AB; Cummings RD -
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 88 Page(s): 146 - 151
07/01/2015 Authors: Bhutani H; Smith V; Rahbari-Oskoui F; Mittal A; Grantham JJ; Torres VE; Mrug M; Bae KT; Wu Z; Ge Y -
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney Int Volume: 88 Page(s): 17 - 27
07/01/2015 Authors: Chapman AB; Devuyst O; Eckardt K-U; Gansevoort RT; Harris T; Horie S; Kasiske BL; Odland D; Pei Y; Perrone RD -
Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy?
Am J Kidney Dis Volume: 65 Page(s): 811 - 813
06/01/2015 Authors: Reddy B; Chapman AB -
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
J Hypertens Volume: 33 Page(s): 1301 - 1309
06/01/2015 Authors: Chittani M; Zaninello R; Lanzani C; Frau F; Ortu MF; Salvi E; Fresu G; Citterio L; Braga D; Piras DA -
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
Metab Syndr Relat Disord Volume: 13 Page(s): 195 - 202
06/01/2015 Authors: Weng L; Quinlivan E; Gong Y; Beitelshees AL; Shahin MH; Turner ST; Chapman AB; Gums JG; Johnson JA; Frye RF -
URINARY PROTEOMIC BIOMARKERS, A POWERFUL TOOL FOR PROGNOSIS OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PROGRESSION
Volume: 30
05/01/2015 Authors: Pejchinovski M; Siwy J; Metzger J; Mischak H; Jankowski V; Chapman AB; Kistler AD -
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.
Pharmacogenomics J Volume: 15 Page(s): 153 - 157
04/01/2015 Authors: Del-Aguila JL; Cooper-DeHoff RM; Chapman AB; Gums JG; Beitelshees AL; Bailey K; Turner ST; Johnson JA; Boerwinkle E -
METABOLOMICS, GENOMICS AND LIPIDOMICS REVEAL NOVEL SIGNATURES OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S30 - S30
02/01/2015 Authors: Shahin MH; Gong Y; Langaee T; Beitel-Shees AL; Rotroff DM; Chapman AB; Gums JG; Turner ST; Motsinger-Reif A; Frye RF -
INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S2 - S2
02/01/2015 Authors: Shahin MH; Rotroff DM; Gong Y; Langaee T; McDonough CW; Beitelshees AL; Garrett TJ; Chapman AB; Gums JG; Turner ST -
CORRELATING THE MELATONIN (MT) PATHWAY WITH ATENOLOL ASSOCIATED GLUCOSE DYSREGULATION IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S17 - S17
02/01/2015 Authors: Chang S; Gong Y; McDonough CW; Kenari NN; Langaee T; Beitelshees AL; Gums JG; Chapman AB; Turner ST; Johnson JA -
INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S11 - S11
02/01/2015 Authors: Shahin MH; Rotroff DM; Gong Y; Langaee T; McDonough CW; Beitelshees AL; Garrett TJ; Chapman AB; Gums JG; Turner ST -
METABOLOMICS, GENOMICS AND LIPIDOMICS REVEAL NOVEL SIGNATURES OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S4 - S5
02/01/2015 Authors: Shahin MH; Gong Y; Langaee T; Beitelshees AL; Rotroff DM; Chapman AB; Gums JG; Turner ST; Motsinger-Reif A; Frye RF -
INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 97 Page(s): S103 - S103
02/01/2015 Authors: Shahin MH; Rotroff DM; Gong Y; Langaee T; McDonough CW; Beitelshees AL; Garrett TJ; Chapman AB; Gums JG; Turner ST -
Does dopamine connect the dots in ADPKD?
Kidney Int Volume: 87 Page(s): 279 - 280
02/01/2015 Authors: Chapman AB -
Pharmacogenomics of hypertension: a genomewide, placebocontrolled crossover study, using four classes of antihypertensive drugs.
J Am Heart Assoc Volume: 4 Page(s): e001521
01/26/2015 Authors: Hiltunen TP; Donner KM; Sarin A-P; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F -
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication.
PLoS One Volume: 10 Page(s): e0113808
01/01/2015 Authors: Langaee T; Hamadeh I; Chapman AB; Gums JG; Johnson JA -
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.
J Am Soc Nephrol Volume: 26 Page(s): 160 - 172
01/01/2015 Authors: Irazabal MV; Rangel LJ; Bergstralh EJ; Osborn SL; Harmon AJ; Sundsbak JL; Bae KT; Chapman AB; Grantham JJ; Mrug M -
Liver involvement in early autosomal-dominant polycystic kidney disease.
Clin Gastroenterol Hepatol Volume: 13 Page(s): 155 - 64.e6
01/01/2015 Authors: Hogan MC; Abebe K; Torres VE; Chapman AB; Bae KT; Tao C; Sun H; Perrone RD; Steinman TI; Braun W -
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
N Engl J Med Volume: 371 Page(s): 2267 - 2276
12/11/2014 Authors: Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC -
Blood pressure in early autosomal dominant polycystic kidney disease.
N Engl J Med Volume: 371 Page(s): 2255 - 2266
12/11/2014 Authors: Schrier RW; Abebe KZ; Perrone RD; Torres VE; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC -
Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant Volume: 29 Page(s): 2194 - 2201
12/01/2014 Authors: Rahbari-Oskoui F; Williams O; Chapman A -
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
J Am Heart Assoc Volume: 3 Page(s): e001398
11/10/2014 Authors: Fontana V; McDonough CW; Gong Y; El Rouby NM; S ACC; Taylor KD; Chen Y-DI; Gums JG; Chapman AB; Turner ST -
Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals.
Mol Cell Proteomics Volume: 13 Page(s): 3097 - 3113
11/01/2014 Authors: Lehoux S; Mi R; Aryal RP; Wang Y; Schjoldager KT-BG; Clausen H; van Die I; Han Y; Chapman AB; Cummings RD -
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Pharmacotherapy Volume: 34 Page(s): 1132 - 1140
11/01/2014 Authors: Moore MJ; Gong Y; Hou W; Hall K; Schmidt SOF; Curry RW; Beitelshees AL; Chapman A; Turner ST; Schwartz GL -
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
J Intern Med Volume: 276 Page(s): 486 - 497
11/01/2014 Authors: Vandell AG; McDonough CW; Gong Y; Langaee TY; Lucas AM; Chapman AB; Gums JG; Beitelshees AL; Bailey KR; Johnson RJ -
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Clin Pharmacol Ther Volume: 96 Page(s): 175 - 181
08/01/2014 Authors: Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y -
URINE OSMOLALITY AND OUTCOME IN ADPKD: RESULTS FROM THE TEMPO 3:4 TRIAL
Volume: 29 Page(s): 6 - 6
05/01/2014 Authors: Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Torres VE; Krasa HB; Ouyang J; Shoaf S -
RELATIONSHIP OF TOTAL KIDNEY VOLUME, GROWTH, CKD STAGE AND KIDNEY PAIN IN ADPKD: EXAMINATION OF THE OVERTURE TRIAL BASELINE DATA
Volume: 29 Page(s): 74 - 74
05/01/2014 Authors: Perrone RD; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Torres VE; Sergeyeva O; Zhou W -
TOLVAPTAN-TREATMENT OF ADPKD CONFERS PERSISTENT EGFR IMPROVEMENT: RESULTS FROM THE TEMPO 4:4 EXTENSION TRIAL
Volume: 29 Page(s): 6 - 6
05/01/2014 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Higashihara E; Perrone RD; Ouyang J; Shoaf SE; Dandurand A; McQuade RD -
CHARACTERISTICS OF ADPKD PATIENTS WITH RAPID PROGRESSION TO RENAL FAILURE: LESSONS FROM CRISP.
Volume: 63 Page(s): A37 - A37
05/01/2014 Authors: Chapman AB; Gibbs P; Rahbari-Oskoui F; Bae T; Bhutani HS; Grantham J; Harris P; Mrug M; Torres V; Yu A -
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
Am J Hypertens Volume: 27 Page(s): 546 - 554
04/01/2014 Authors: Chapman AB; Cotsonis G; Parekh V; Schwartz GL; Gong Y; Bailey KR; Turner ST; Gums JG; Beitelshees AL; Cooper-DeHoff R -
Is diabetes mellitus-linked amino acid signature associated with -blocker-induced impaired fasting glucose?
Circ Cardiovasc Genet Volume: 7 Page(s): 199 - 205
04/01/2014 Authors: Cooper-Dehoff RM; Hou W; Weng L; Baillie RA; Beitelshees AL; Gong Y; Shahin MHA; Turner ST; Chapman A; Gums JG -
GENOME-WIDE ASSOCIATION ANALYSIS (GWAS) OF BLOOD PRESSURE RESPONSE TO ATENOLOL-RESULTS FROM THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY
Volume: 95 Page(s): S16 - S17
03/01/2014 Authors: Gong Y; McDonough CW; Wang Z; Langaee TY; Beitelshees AL; Gums JG; Bailey KR; Boerwinkle E; Chapman AB; Turner ST -
Baseline predictors of central aortic blood pressure: a PEAR substudy.
J Am Soc Hypertens Volume: 8 Page(s): 152 - 158
03/01/2014 Authors: Rosenwasser RF; Shah NK; Smith SM; Wen X; Gong Y; Gums JG; Nichols WW; Chapman AB; Boerwinkle E; Johnson J -
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy Volume: 34 Page(s): 123 - 130
02/01/2014 Authors: Gong Y; McDonough CW; Beitelshees AL; Karnes JH; O'Connell JR; Turner ST; Chapman AB; Gums JG; Bailey KR; Boerwinkle E -
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.
Pharmacogenomics J Volume: 14 Page(s): 35 - 40
02/01/2014 Authors: Del-Aguila JL; Beitelshees AL; Cooper-Dehoff RM; Chapman AB; Gums JG; Bailey K; Gong Y; Turner ST; Johnson JA; Boerwinkle E -
Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 9 Page(s): 406 - 415
02/01/2014 Authors: Rahbari-Oskoui F; Mittal A; Mittal P; Chapman A -
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Am J Kidney Dis Volume: 63 Page(s): 214 - 226
02/01/2014 Authors: Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC -
The importance of quantifying genetic heterogeneity in ADPKD.
Kidney Int Volume: 85 Page(s): 236 - 237
02/01/2014 Authors: Chapman AB -
Novel methodology to evaluate renal cysts in polycystic kidney disease.
Am J Nephrol Volume: 39 Page(s): 210 - 217
01/01/2014 Authors: Bae KT; Sun H; Lee JG; Bae K; Wang J; Tao C; Chapman AB; Torres VE; Grantham JJ; Mrug M -
Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment.
PLoS One Volume: 9 Page(s): e86223
01/01/2014 Authors: Kim K; Mall C; Taylor SL; Hitchcock S; Zhang C; Wettersten HI; Jones AD; Chapman A; Weiss RH -
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
Pharmacogenomics J Volume: 13 Page(s): 430 - 436
10/01/2013 Authors: Karnes JH; McDonough CW; Gong Y; Vo TT; Langaee TY; Chapman AB; Gums JG; Beitelshees AL; Bailey KR; Del-Aguila JL -
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
Am J Hypertens Volume: 26 Page(s): 957 - 964
08/01/2013 Authors: Schwartz GL; Bailey K; Chapman AB; Boerwinkle E; Turner ST -
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Hypertension Volume: 62 Page(s): 391 - 397
08/01/2013 Authors: Turner ST; Boerwinkle E; O'Connell JR; Bailey KR; Gong Y; Chapman AB; McDonough CW; Beitelshees AL; Schwartz GL; Gums JG -
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 8 Page(s): 1089 - 1097
07/01/2013 Authors: Bae K; Park B; Sun H; Wang J; Tao C; Chapman AB; Torres VE; Grantham JJ; Mrug M; Bennett WM -
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
Pharmacogenomics J Volume: 13 Page(s): 257 - 263
06/01/2013 Authors: Duarte JD; Turner ST; Tran B; Chapman AB; Bailey KR; Gong Y; Gums JG; Langaee TY; Beitelshees AL; Cooper-Dehoff RM -
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (PKD) EVALUATED FOR RENAL TRANSPLANTATION. A SINGLE CENTER EXPERIENCE
Volume: 61 Page(s): A66 - A66
04/01/2013 Authors: Mittal A; Rao S; Chami A; Perez S; Chapman AB -
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
J Hypertens Volume: 31 Page(s): 698 - 704
04/01/2013 Authors: McDonough CW; Burbage SE; Duarte JD; Gong Y; Langaee TY; Turner ST; Gums JG; Chapman AB; Bailey KR; Beitelshees AL -
FASTING GLUCOSE LOCI ASSOCIATED WITH GLUCOSE RESPONSE TO ANTIHYPERTENSIVES- RESULTS FROM THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY
Volume: 93 Page(s): S28 - S28
02/01/2013 Authors: Gong Y; Moore MJ; Karnes JH; McDonough CW; Wang Z; Langaee TY; Beitelshees AL; Turner ST; Chapman AB; Gums JG -
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PLoS One Volume: 8 Page(s): e76984
01/01/2013 Authors: McDonough CW; Gillis NK; Alsultan A; Chang S-W; Kawaguchi-Suzuki M; Lang JE; Shahin MHA; Buford TW; El Rouby NM; S ACC -
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.
Am J Nephrol Volume: 38 Page(s): 333 - 341
01/01/2013 Authors: Bae KT; Tao C; Wang J; Kaya D; Wu Z; Bae JT; Chapman AB; Torres VE; Grantham JJ; Mrug M -
Response to genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
Hypertension Volume: 61 Page(s): e6
01/01/2013 Authors: Chai HS; Chapman AB; Boerwinkle E -
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
PLoS One Volume: 8 Page(s): e57639
01/01/2013 Authors: Wikoff WR; Frye RF; Zhu H; Gong Y; Boyle S; Churchill E; Cooper-Dehoff RM; Beitelshees AL; Chapman AB; Fiehn O -
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
PLoS One Volume: 8 Page(s): e53016
01/01/2013 Authors: Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE -
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.
PLoS One Volume: 8 Page(s): e52062
01/01/2013 Authors: Le MT; Lobmeyer MT; Campbell M; Cheng J; Wang Z; Turner ST; Chapman AB; Boerwinkle E; Gums JG; Gong Y -
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
N Engl J Med Volume: 367 Page(s): 2407 - 2418
12/20/2012 Authors: Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS -
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circ Cardiovasc Genet Volume: 5 Page(s): 686 - 691
12/01/2012 Authors: Gong Y; McDonough CW; Wang Z; Hou W; Cooper-DeHoff RM; Langaee TY; Beitelshees AL; Chapman AB; Gums JG; Bailey KR -
Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen.
J Biol Chem Volume: 287 Page(s): 41523 - 41533
11/30/2012 Authors: Mi R; Song L; Wang Y; Ding X; Zeng J; Lehoux S; Aryal RP; Wang J; Crew VK; van Die I -
Pharmacometabolomics Reveals a Novel Signature for Predicting Beta Blocker Associated Impaired Fasting Glucose
Volume: 126
11/20/2012 Authors: Cooper-DeHoff RM; Hou W; Baillie R; Beitelshees AL; Gong Y; Chapman AB; Gums JG; Turner ST; Boyle SH; Zhu H -
Epigenetic silencing of Cosmc in leukocytes expressing Tn antigen
Volume: 22 Page(s): 1526 - 1526
11/01/2012 Authors: Mi R; Song L; Wang Y; Ding X; Zeng J; Arayl RP; Crew VK; van Die I; Chapman AB; Cummings RD -
Characterization of the mucin-type O-glycans in IgA1 from patients with IgA nephropathy and healthy individuals
Volume: 22 Page(s): 1567 - 1567
11/01/2012 Authors: Lehoux S; Mi R; Aryal R; Wang Y; Schjoldager KTBG; Clausen H; van Die I; Chapman AB; Cummings RD; Ju T -
G protein receptor kinase 4 polymorphisms: -blocker pharmacogenetics and treatment-related outcomes in hypertension.
Hypertension Volume: 60 Page(s): 957 - 964
10/01/2012 Authors: Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM -
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
Hypertension Volume: 59 Page(s): 1204 - 1211
06/01/2012 Authors: Turner ST; Bailey KR; Schwartz GL; Chapman AB; Chai HS; Boerwinkle E -
The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 81 Page(s): 814 - 815
05/01/2012 Authors: Chapman AB -
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.
Kidney Int Volume: 81 Page(s): 784 - 790
04/01/2012 Authors: Parikh CR; Dahl NK; Chapman AB; Bost JE; Edelstein CL; Comer DM; Zeltner R; Tian X; Grantham JJ; Somlo S -
Cosmc Is Silenced in Human Tn4 B Cells through Hypermethylation of the Gene Promoter
Volume: 26
04/01/2012 Authors: Ju T; Mi R; Song L; Wang Y; Ding X; Crew VK; Lehoux SD; van Die I; Chapman AB; Cummings RD -
Human Cosmc and T-synthase Genes Are Transcriptionally Regulated by SP1/SP3 Transcription Factors
Volume: 26
04/01/2012 Authors: Ju T; Mi R; Wang Y; Ding X; Song L; van Die I; Chapman AB; Cummings RD -
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
J Transl Med Volume: 10 Page(s): 56
03/22/2012 Authors: Duarte JD; Zineh I; Burkley B; Gong Y; Langaee TY; Turner ST; Chapman AB; Boerwinkle E; Gums JG; Cooper-Dehoff RM -
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
J Transl Med Volume: 10 Page(s): 47
03/13/2012 Authors: Turner ST; Schwartz GL; Chapman AB; Beitelshees AL; Gums JG; Cooper-Dehoff RM; Boerwinkle E; Johnson JA; Bailey KR -
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
Am J Hypertens Volume: 25 Page(s): 359 - 365
03/01/2012 Authors: Smith SM; Gong Y; Turner ST; Cooper-DeHoff RM; Beitelshees AL; Chapman AB; Boerwinkle E; Bailey K; Johnson JA; Gums JG -
ASSOCIATION OF FTO WITH HYDROCHLOROTHIAZIDE (HCTZ)-INDUCED ELEVATION IN URIC ACID (UA) IN AFRICAN AMERICAN (AA) HYPERTENSIVES IN THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSE (PEAR) STUDY.
Volume: 91 Page(s): S59 - S60
03/01/2012 Authors: Vandell AG; McDonough CW; Langaee TY; Burkley B; Gong Y; Turner ST; Gums JG; Chapman AB; Beitelshees AL; Bailey KR -
Analysis of baseline parameters in the HALT polycystic kidney disease trials.
Kidney Int Volume: 81 Page(s): 577 - 585
03/01/2012 Authors: Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT -
HYPERTENSION SUSCEPTIBILITY LOCI ASSOCIATED WITH BLOOD PRESSURE RESPONSE TO ANTIHYPERTENSIVES- RESULTS FROM THE PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
Volume: 91 Page(s): S16 - S16
03/01/2012 Authors: Gong Y; McDonough CW; Wang Z; Cooper-DeHoff RM; Langaee TY; Beitelshee AL; Turner ST; Chapman AB; Gums JG; Bailey KR -
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 7 Page(s): 479 - 486
03/01/2012 Authors: Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH -
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension.
Kidney Blood Press Res Volume: 35 Page(s): 477 - 482
01/01/2012 Authors: Shafiu M; Johnson RJ; Turner ST; Langaee T; Gong Y; Chapman AB; Gums JG; Johnson JA -
Human Cosmc and T-synthase are Transcriptionally Regulated by SP1 Transcription Factor
Volume: 21 Page(s): 1488 - 1488
11/01/2011 Authors: Mi R; Wang Y; Ding X; Van Die I; Chapman AB; Cummings RD; Ju T -
Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 6 Page(s): 2508 - 2515
10/01/2011 Authors: Perrone RD; Abebe KZ; Schrier RW; Chapman AB; Torres VE; Bost J; Kaya D; Miskulin DC; Steinman TI; Braun W -
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
Clin J Am Soc Nephrol Volume: 6 Page(s): 2499 - 2507
10/01/2011 Authors: Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB -
Imaging approaches to patients with polycystic kidney disease.
Semin Nephrol Volume: 31 Page(s): 237 - 244
05/01/2011 Authors: Chapman AB; Wei W -
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Am J Kidney Dis Volume: 57 Page(s): 692 - 699
05/01/2011 Authors: Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB -
Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.
Blood Press Monit Volume: 16 Page(s): 47 - 54
04/01/2011 Authors: Rahbari-Oskoui FF; Miskulin DC; Hogan MC; Fielder O; Torres VE; Bost JE; Chapman AB -
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 6 Page(s): 640 - 647
03/01/2011 Authors: Torres VE; Grantham JJ; Chapman AB; Mrug M; Bae KT; King BF; Wetzel LH; Martin D; Lockhart ME; Bennett WM -
INFLUENCE OF G PROTEIN RECEPTOR KINASE 4 (GRK4) POLYMORPHISMS ON BLOOD PRESSURE RESPONSE TO THE beta-BLOCKER ATENOLOL.
Volume: 89 Page(s): S74 - S74
02/01/2011 Authors: Vandell AG; Lobmeyer MT; Gawronski B; Langaee TY; Gong Y; Beitelshees AL; Gums JG; Turner ST; Chapman AB; Cooper-DeHoff RM -
KCNJ1 SNPS ARE ASSOCIATED WITH INCREASED FASTING GLUCOSE AND RISK OF NEW ONSET DIABETES DURING HCTZ THERAPY
Volume: 89 Page(s): S46 - S46
02/01/2011 Authors: Karnes JH; Vo TT; Gong Y; Langaee TY; Beitelshees AL; Turner ST; Chapman AB; Gums JG; Bailey K; Boerwinkle E -
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Pharmacogenet Genomics Volume: 21 Page(s): 42 - 49
01/01/2011 Authors: Lobmeyer MT; Wang L; Zineh I; Turner ST; Gums JG; Chapman AB; Cooper-DeHoff RM; Beitelshees AL; Bailey KR; Boerwinkle E -
Nephrology fellows show consistent use of, and improved knowledge from, a nephrologist-programmed teaching instrument.
J Nephrol Volume: 24 Page(s): 345 - 350
01/01/2011 Authors: Desai T; Stankeyeva D; Chapman A; Bailey J -
Renal CD14 expression correlates with the progression of cystic kidney disease.
Kidney Int Volume: 78 Page(s): 550 - 560
09/01/2010 Authors: Zhou J; Ouyang X; Cui X; Schoeb TR; Smythies LE; Johnson MR; Guay-Woodford LM; Chapman AB; Mrug M -
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
Am J Hypertens Volume: 23 Page(s): 1014 - 1022
09/01/2010 Authors: Turner ST; Schwartz GL; Chapman AB; Beitelshees AL; Gums JG; Cooper-DeHoff RM; Boerwinkle E; Johnson JA; Bailey KR -
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide.
Pharmacogenet Genomics Volume: 20 Page(s): 516 - 519
08/01/2010 Authors: Duarte JD; Lobmeyer MT; Wang Z; Chapman AB; Gums JG; Langaee TY; Boerwinkle E; Turner ST; Johnson JA -
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.
Clin J Am Soc Nephrol Volume: 5 Page(s): 1312 - 1329
07/01/2010 Authors: Torres VE; Boletta A; Chapman A; Gattone V; Pei Y; Qian Q; Wallace DP; Weimbs T; Wthrich RP -
Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects.
Magn Reson Med Volume: 63 Page(s): 940 - 950
04/01/2010 Authors: Dambreville S; Chapman AB; Torres VE; King BF; Wallin AK; Frakes DH; Yoganathan AP; Wijayawardana SR; Easley K; Bae KT -
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease.
Am J Physiol Renal Physiol Volume: 298 Page(s): F909 - F922
04/01/2010 Authors: Taylor SL; Ganti S; Bukanov NO; Chapman A; Fiehn O; Osier M; Kim K; Weiss RH -
Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response to Atenol and Hydrochlorthiazide (vol 12, pg 14, 2010)
JOURNAL OF CLINICAL HYPERTENSION Volume: 12 Page(s): 192 - 192
03/01/2010 Authors: Beitelshees AL; Gong Y; Bailey KR; Turner ST; Chapman AB; Schwartz GL; Gums JG; Boerwinkle E; Johnson JA -
Hypertension in autosomal dominant polycystic kidney disease.
Adv Chronic Kidney Dis Volume: 17 Page(s): 153 - 163
03/01/2010 Authors: Chapman AB; Stepniakowski K; Rahbari-Oskoui F -
YEATS4 GENE REGION POLYMORPHISMS ASSOCIATE WITH ANTIHYPERTENSIVE RESPONSE TO HYDROCHLOROTHIAZIDE IN AFRICAN AMERICANS.
Volume: 87 Page(s): S46 - S46
02/01/2010 Authors: Duarte JD; Tran BC; Langaee TY; Chapman AB; Gums JG; Boerwinkle E; Turner ST; Johnson JA -
ASSOCIATION BETWEEN MELATONIN RECEPTOR 1B SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) AND RESPONSE TO ANTIHYPERTENSIVE DRUGS.
Volume: 87 Page(s): S45 - S45
02/01/2010 Authors: Moore MJ; Chik VP; Gong Y; Langaee T; Chapman AB; Schwartz GL; Turner ST; Gums JG; Cooper-DeHoff RM; Beitelshees AL -
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols.
J Magn Reson Imaging Volume: 31 Page(s): 440 - 446
02/01/2010 Authors: Martin DR; Krishnamoorthy SK; Kalb B; Salman KN; Sharma P; Carew JD; Martin PA; Chapman AB; Ray GL; Larsen CP -
The HALT polycystic kidney disease trials: design and implementation.
Clin J Am Soc Nephrol Volume: 5 Page(s): 102 - 109
01/01/2010 Authors: Chapman AB; Torres VE; Perrone RD; Steinman TI; Bae KT; Miller JP; Miskulin DC; Rahbari Oskoui F; Masoumi A; Hogan MC -
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide.
J Clin Hypertens (Greenwich) Volume: 12 Page(s): 14 - 21
01/01/2010 Authors: Beitelshees AL; Gong Y; Bailey KR; Turner ST; Chapman AB; Schwartz GL; Gums JG; Boerwinkle E; Johnson JA -
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension Volume: 55 Page(s): 61 - 68
01/01/2010 Authors: Cooper-DeHoff RM; Wen S; Beitelshees AL; Zineh I; Gums JG; Turner ST; Gong Y; Hall K; Parekh V; Chapman AB -
Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients.
J Magn Reson Imaging Volume: 30 Page(s): 1350 - 1356
12/01/2009 Authors: Martin DR; Semelka RC; Chapman A; Peters H; Finn PJ; Kalb B; Thomsen H -
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Clin Pharmacol Ther Volume: 86 Page(s): 533 - 539
11/01/2009 Authors: Johnson JA; Gong Y; Bailey KR; Cooper-DeHoff RM; Chapman AB; Turner ST; Schwartz GL; Campbell K; Schmidt S; Beitelshees AL -
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy Volume: 29 Page(s): 1157 - 1165
10/01/2009 Authors: Smith SM; Anderson SD; Wen S; Gong Y; Turner ST; Cooper-Dehoff RM; Schwartz GL; Bailey K; Chapman A; Hall KL -
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study.
Physiol Genomics Volume: 39 Page(s): 56 - 60
09/09/2009 Authors: Barbalic M; Schwartz GL; Chapman AB; Turner ST; Boerwinkle E -
Polycystic kidney disease: The cadence of kidney growth in ADPKD.
Nat Rev Nephrol Volume: 5 Page(s): 311 - 312
06/01/2009 Authors: Chapman A -
Renal volume in children with ADPKD: size matters.
Clin J Am Soc Nephrol Volume: 4 Page(s): 698 - 699
04/01/2009 Authors: Chapman AB; Guay-Woodford LM -
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement.
Clin J Am Soc Nephrol Volume: 4 Page(s): 719 - 725
04/01/2009 Authors: Bae KT; Tao C; Zhu F; Bost JE; Chapman AB; Grantham JJ; Torres VE; Guay-Woodford LM; Meyers CM; Bennett WM -
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
Clin J Am Soc Nephrol Volume: 4 Page(s): 560 - 566
03/01/2009 Authors: Rizk D; Jurkovitz C; Veledar E; Bagby S; Baumgarten DA; Rahbari-Oskoui F; Steinman T; Chapman AB -
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
Am Heart J Volume: 157 Page(s): 442 - 449
03/01/2009 Authors: Johnson JA; Boerwinkle E; Zineh I; Chapman AB; Bailey K; Cooper-DeHoff RM; Gums J; Curry RW; Gong Y; Beitelshees AL -
Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD.
Kidney Int Volume: 75 Page(s): 139 - 141
01/01/2009 Authors: Chapman AB -
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.
Kidney Int Volume: 74 Page(s): 1468 - 1479
12/01/2008 Authors: Consugar MB; Wong WC; Lundquist PA; Rossetti S; Kubly VJ; Walker DL; Rangel LJ; Aspinwall R; Niaudet WP; Ozen S -
Nurturing passion in a time of academic climate change: the modern-day challenge of junior faculty development.
Clin J Am Soc Nephrol Volume: 3 Page(s): 1878 - 1883
11/01/2008 Authors: Chapman AB; Guay-Woodford LM -
Reproducibility of Genotypes as Measured by the Affymetrix GeneChip 100K Human Mapping Array Set.
Comput Stat Data Anal Volume: 52 Page(s): 5367 - 5374
08/15/2008 Authors: Fridley BL; Turner ST; Chapman A; Rodin A; Boerwinkle E; Bailey K -
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic.
Hypertension Volume: 52 Page(s): 359 - 365
08/01/2008 Authors: Turner ST; Bailey KR; Fridley BL; Chapman AB; Schwartz GL; Chai HS; Sicotte H; Kocher J-P; Rodin AS; Boerwinkle E -
Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.
Pediatr Nephrol Volume: 23 Page(s): 1029 - 1036
07/01/2008 Authors: Rizk D; Chapman A -
Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
Clin J Am Soc Nephrol Volume: 3 Page(s): 1197 - 1204
07/01/2008 Authors: Chapman AB -
Determinants of renal volume in autosomal-dominant polycystic kidney disease.
Kidney Int Volume: 73 Page(s): 108 - 116
01/01/2008 Authors: Grantham JJ; Cook LT; Torres VE; Bost JE; Chapman AB; Harris PC; Guay-Woodford LM; Bae KT -
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
Am J Hypertens Volume: 21 Page(s): 61 - 66
01/01/2008 Authors: Canzanello VJ; Baranco-Pryor E; Rahbari-Oskoui F; Schwartz GL; Boerwinkle E; Turner ST; Chapman AB -
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
J Am Soc Nephrol Volume: 18 Page(s): 2143 - 2160
07/01/2007 Authors: Rossetti S; Consugar MB; Chapman AB; Torres VE; Guay-Woodford LM; Grantham JJ; Bennett WM; Meyers CM; Walker DL; Bae K -
Primary aldosteronism in diabetic subjects with resistant hypertension.
Diabetes Care Volume: 30 Page(s): 1699 - 1703
07/01/2007 Authors: Umpierrez GE; Cantey P; Smiley D; Palacio A; Temponi D; Luster K; Chapman A -
Autosomal dominant polycystic kidney disease: time for a change?
J Am Soc Nephrol Volume: 18 Page(s): 1399 - 1407
05/01/2007 Authors: Chapman AB -
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
Clin J Am Soc Nephrol Volume: 2 Page(s): 112 - 120
01/01/2007 Authors: Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ -
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension.
Am J Nephrol Volume: 27 Page(s): 212 - 220
01/01/2007 Authors: Levin A; Linas S; Luft FC; Chapman AB; Textor S; ASN HTN Advisory Group -
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.
Volume: 17 Page(s): 3013 - 3019
11/01/2006 Authors: Harris PC; Bae KT; Rossetti S; Torres VE; Grantham JJ; Chapman AB; Guay-Woodford LM; King BF; Wetzel LH; Baumgarten DA -
Volume progression in polycystic kidney disease.
N Engl J Med Volume: 354 Page(s): 2122 - 2130
05/18/2006 Authors: Grantham JJ; Torres VE; Chapman AB; Guay-Woodford LM; Bae KT; King BF; Wetzel LH; Baumgarten DA; Kenney PJ; Harris PC -
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
J Am Soc Nephrol Volume: 17 Page(s): 854 - 862
03/01/2006 Authors: Rule AD; Torres VE; Chapman AB; Grantham JJ; Guay-Woodford LM; Bae KT; Klahr S; Bennett WM; Meyers CM; Thompson PA -
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
Clin J Am Soc Nephrol Volume: 1 Page(s): 64 - 69
01/01/2006 Authors: Bae KT; Zhu F; Chapman AB; Torres VE; Grantham JJ; Guay-Woodford LM; Baumgarten DA; King BF; Wetzel LH; Kenney PJ -
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.
Clin J Am Soc Nephrol Volume: 1 Page(s): 148 - 157
01/01/2006 Authors: Grantham JJ; Chapman AB; Torres VE -
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP).
Am J Kidney Dis Volume: 46 Page(s): 1058 - 1064
12/01/2005 Authors: O'Neill WC; Robbin ML; Bae KT; Grantham JJ; Chapman AB; Guay-Woodford LM; Torres VE; King BF; Wetzel LH; Thompson PA -
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic.
Hypertension Volume: 46 Page(s): 758 - 765
10/01/2005 Authors: Turner ST; Schwartz GL; Chapman AB; Boerwinkle E -
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects.
Am J Hypertens Volume: 18 Page(s): 1077 - 1083
08/01/2005 Authors: Maitland-van der Zee A-H; Turner ST; Schwartz GL; Chapman AB; Klungel OH; Boerwinkle E -
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide.
Pharmacogenet Genomics Volume: 15 Page(s): 287 - 293
05/01/2005 Authors: Maitland-van der Zee A-H; Turner ST; Schwartz GL; Chapman AB; Klungel OH; Boerwinkle E -
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.
Am J Hypertens Volume: 18 Page(s): 398 - 402
03/01/2005 Authors: Finkielman JD; Schwartz GL; Chapman AB; Boerwinkle E; Turner ST -
Multilocus approach to the pharmacogenetics of thiazide diuretics
Volume: 110 Page(s): 428 - 428
10/26/2004 Authors: Maitland-van der Zee AH; Turner ST; Chapman AB; Schwartz GL; Klungel OH; Boerwinkle E -
Medullary cystic kidney disease type 2.
Am J Kidney Dis Volume: 43 Page(s): 1142
06/01/2004 Authors: Bleyer AJ; Hart TC -
Medullary cystic kidney disease type 2 - In reply
AMERICAN JOURNAL OF KIDNEY DISEASES Volume: 43 Page(s): 1142 - 1143
06/01/2004 Authors: Chapman AB; Rizk D -
Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic.
Pharmacogenomics J Volume: 4 Page(s): 17 - 23
01/01/2004 Authors: Frazier L; Turner ST; Schwartz GL; Chapman AB; Boerwinkle E -
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
Kidney Int Volume: 64 Page(s): 2214 - 2221
12/01/2003 Authors: King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM -
Cystic and inherited kidney diseases.
Am J Kidney Dis Volume: 42 Page(s): 1305 - 1317
12/01/2003 Authors: Rizk D; Chapman AB -
The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease.
Kidney Int Volume: 64 Page(s): 1792 - 1799
11/01/2003 Authors: Schrier RW; Johnson AM; McFann K; Chapman AB -
A prospective examination of the relation between MCP-1 and disease status in non-azotemic patients with autosomal dominant PKD
Volume: 14 Page(s): 875A - 876A
11/01/2003 Authors: Grantham JJ; Zheng DX; Torres VE; Chapman AB; Guay-Woodford LM; Bae KT; Miller JP; Bennett W; Hirschman GH -
Magnetic resonance imaging (MRI) determination of mouse kidney volume
Volume: 14 Page(s): 146A - 146A
11/01/2003 Authors: Paxton WG; Long RC; Brummer ME; Chapman AB -
Predictive value of renal hemodynamic parameters on kidney volume and glomerular filtration rate (GFR) changes in early ADPKD.
Volume: 14 Page(s): 108A - 108A
11/01/2003 Authors: Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Thompson PA; Miller JP -
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide.
Am J Hypertens Volume: 16 Page(s): 834 - 839
10/01/2003 Authors: Turner ST; Chapman AB; Schwartz GL; Boerwinkle E -
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Kidney Int Volume: 64 Page(s): 1035 - 1045
09/01/2003 Authors: Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH -
Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease.
Kidney Int Volume: 63 Page(s): 1824 - 1830
05/01/2003 Authors: Belz MM; Fick-Brosnahan GM; Hughes RL; Rubinstein D; Chapman AB; Johnson AM; McFann KK; Kaehny WD; Gabow PA -
Efficient and reliable genotype determination by gene linkage analysis in autosomal dominant polycystic kidney disease (ADPKD)
Volume: 51 Page(s): S312 - S312
02/01/2003 Authors: Paxton WG; Lamb NE; Sherman SI; Chapman AB -
Autosomal dominant polycystic kidney disease (ADPKD) patients not yet on dialysis demonstrate a lower quality of life (by SF-36) than the general population.
Volume: 51 Page(s): S271 - S271
02/01/2003 Authors: Rizk D; Ladson J; Jurkovitz CT; Veledar E; Post R; Chapman AB -
Cystic disease in women: clinical characteristics and medical management.
Adv Ren Replace Ther Volume: 10 Page(s): 24 - 30
01/01/2003 Authors: Chapman AB -
Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide.
Kidney Int Volume: 62 Page(s): 1718 - 1723
11/01/2002 Authors: Schwartz GL; Turner ST; Chapman AB; Boerwinkle E -
Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio.
Clin Chem Volume: 48 Page(s): 1919 - 1923
11/01/2002 Authors: Schwartz GL; Chapman AB; Boerwinkle E; Kisabeth RM; Turner ST -
Magnetic resonance imaging (MRI) in early autosomal dominant polycystic kidney disease (ADPKD): Baseline characteristics of the Consortium for Radiographic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Volume: 13 Page(s): 507A - 507A
09/01/2002 Authors: Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Kimmel PL; Hirschman GH; Miller PJ; Bae T -
Basal systemic, adrenal and renal responses to angiotensin converting enzyme inhibitor (Enalapril (En) 20 mg), angiotensin receptor blocker (Losartan (Los) 50 mg) vs. combination therapy in autosomal dominant polycystic kidney disease (PKD)
Volume: 13 Page(s): 508A - 508A
09/01/2002 Authors: Stepniakowski KT; Gerron GG; Chapman AB -
Magnetic resonance measurements of renal blood flow as a marker of disease progression in autosomal dominant polycystic kidney disease (ADPKD), baseline characteristics.
Volume: 13 Page(s): 506A - 506A
09/01/2002 Authors: King BF; Torres VE; Brummer M; Chapman AB; Glockner JF; Arya K; Miller JP; Bae T -
Dissociation between systemic, adrenal, and renal response to angiotensin converting enzyme inhibition (Enalapril (En) 20 mg/day), angiotensin receptor blocker (Losartan (Los) 50 mg/day) vs combination therapy (En/Los) in subjects with autosomal dominant polycystic kidney disease (PKD) during equimolar intravenous angiotensin I (Ang I) and angtiotensin II (Ang II) infusion
Volume: 13 Page(s): 507A - 508A
09/01/2002 Authors: Stepniakowski KT; Gerron GG; Chapman AB -
Progression of polycystic kidney disease (PKD) evaluated by MR imaging.
Volume: 13 Page(s): 40A - 40A
09/01/2002 Authors: Bae KT; Chapman AB; Grantham JJ; Torres VE; Guay-Woodford L; Klahr S; Miller JP -
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.
J Am Soc Nephrol Volume: 13 Page(s): 1733 - 1739
07/01/2002 Authors: Schrier R; McFann K; Johnson A; Chapman A; Edelstein C; Brosnahan G; Ecder T; Tison L -
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension.
Kidney Int Volume: 61 Page(s): 1047 - 1055
03/01/2002 Authors: Chapman AB; Schwartz GL; Boerwinkle E; Turner ST -
Reproducibility of blood pressure response to hydrochlorothiazide.
J Clin Hypertens (Greenwich) Volume: 4 Page(s): 408 - 412
01/01/2002 Authors: Finkielman JD; Schwartz GL; Chapman AB; Boerwinkle E; Turner ST -
Use of gene markers to guide antihypertensive therapy.
Curr Hypertens Rep Volume: 3 Page(s): 410 - 415
10/01/2001 Authors: Turner ST; Schwartz GL; Chapman AB; Boerwinkle E -
Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.
Mayo Clin Proc Volume: 76 Page(s): 877 - 882
09/01/2001 Authors: Montori VM; Schwartz GL; Chapman AB; Boerwinkle E; Turner ST -
C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic.
Hypertension Volume: 37 Page(s): 739 - 743
02/01/2001 Authors: Turner ST; Schwartz GL; Chapman AB; Boerwinkle E -
Antihypertensive pharmacogenetics: getting the right drug into the right patient.
J Hypertens Volume: 19 Page(s): 1 - 11
01/01/2001 Authors: Turner ST; Schwartz GL; Chapman AB; Hall WD; Boerwinkle E -
Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.
Am J Nephrol Volume: 21 Page(s): 98 - 103
01/01/2001 Authors: Ecder T; Edelstein CL; Fick-Brosnahan GM; Johnson AM; Chapman AB; Gabow PA; Schrier RW -
Antihypertensive pharmacogenetics: The C825T polymorphism of G-protein beta(3) subunit (GNB3) is associated with greater blood pressure (BP) response to diuretic therapy in essential hypertension (EHT)
Volume: 36 Page(s): 684 - 684
10/01/2000 Authors: Turner ST; Schwartz GL; Chapman AB; Boerwinkle E -
Antihypertensive pharmacogenetics: Effects of angiotensin-converting-enzyme (AGE) genotype-by-gender interaction on blood pressure (BP) responses to a thiazide diuretic in essential hypertension (EHT)
Volume: 36 Page(s): 685 - 685
10/01/2000 Authors: Schwartz GL; Turner ST; Chapman AB; Boerwinkle E -
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Am J Kidney Dis Volume: 35 Page(s): 427 - 432
03/01/2000 Authors: Ecder T; Chapman AB; Brosnahan GM; Edelstein CL; Johnson AM; Schrier RW -
Racial variation in autosomal dominant polycystic kidney disease.
Am J Kidney Dis Volume: 35 Page(s): 35 - 39
01/01/2000 Authors: Freedman BI; Soucie JM; Chapman A; Krisher J; McClellan WM -
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant Volume: 14 Page(s): 1113 - 1116
05/01/1999 Authors: Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW -
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy.
Kidney Int Volume: 54 Page(s): 2056 - 2063
12/01/1998 Authors: Chapman AB; Abraham WT; Zamudio S; Coffin C; Merouani A; Young D; Johnson A; Osorio F; Goldberg C; Moore LG -
The structure-function relationship in preeclampsia.
Kidney Int Volume: 54 Page(s): 1394 - 1395
10/01/1998 Authors: Chapman AB -
Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy.
Am J Physiol Volume: 273 Page(s): F777 - F782
11/01/1997 Authors: Chapman AB; Zamudio S; Woodmansee W; Merouani A; Osorio F; Johnson A; Moore LG; Dahms T; Coffin C; Abraham WT -
Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy.
Am J Physiol Renal Physiol Volume: 273 Page(s): F777 - F782
11/01/1997 Authors: Chapman AB; Zamudio S; Woodmansee W; Merouani A; Osorio F; Johnson A; Moore LG; Dahms T; Coffin C; Abraham WT -
Hypertension in autosomal dominant polycystic kidney disease.
Kidney Int Suppl Volume: 61 Page(s): S71 - S73
10/01/1997 Authors: Chapman AB; Gabow PA -
Left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
J Am Soc Nephrol Volume: 8 Page(s): 1292 - 1297
08/01/1997 Authors: Chapman AB; Johnson AM; Rainguet S; Hossack K; Gabow P; Schrier RW -
Renal artery stenosis and unilateral focal and segmental glomerulosclerosis.
Am J Kidney Dis Volume: 29 Page(s): 936 - 941
06/01/1997 Authors: Alkhunaizi AM; Chapman A -
Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.
J Am Soc Nephrol Volume: 5 Page(s): 1349 - 1354
12/01/1994 Authors: Chapman AB; Johnson AM; Gabow PA; Schrier RW -
Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease.
J Am Soc Nephrol Volume: 5 Page(s): 1178 - 1185
11/01/1994 Authors: Chapman AB; Johnson AM; Gabow PA -
THE ROLE OF PARENTAL HYPERTENSION (HBP) IN THE FREQUENCY AND AGE-OF-ONSET OF HBP IN AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE (PKD) OFFSPRING (O)
Volume: 5 Page(s): 643 - 643
09/01/1994 Authors: CHAPMAN AB; JOHNSON AM; GABOW PA; SCHRIER RW -
Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: how to diagnose and who to screen.
Am J Kidney Dis Volume: 22 Page(s): 526 - 531
10/01/1993 Authors: Chapman AB; Johnson AM; Gabow PA -
Autosomal recessive polycystic kidney disease: issues regarding the variability of clinical presentation.
J Am Soc Nephrol Volume: 3 Page(s): 1858 - 1862
06/01/1993 Authors: Shaikewitz ST; Chapman A -
BLOOD-PRESSURE AND RENAL HEMODYNAMIC-CHANGES DURING THE HUMAN MENSTRUAL-CYCLE
Volume: 41 Page(s): A22 - A22
02/01/1993 Authors: WOODMANSEE WW; CHAPMAN AB; JOHNSON AM; SCHRIER RW -
Intracranial aneurysms in autosomal dominant polycystic kidney disease.
N Engl J Med Volume: 327 Page(s): 916 - 920
09/24/1992 Authors: Chapman AB; Rubinstein D; Hughes R; Stears JC; Earnest MP; Johnson AM; Gabow PA; Kaehny WD -
Polycystic kidney disease and angiotensin-converting enzyme inhibitors.
Ann Intern Med Volume: 117 Page(s): 90
07/01/1992 Authors: Bursztyn M -
Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease.
Ann Intern Med Volume: 115 Page(s): 769 - 773
11/15/1991 Authors: Chapman AB; Gabow PA; Schrier RW -
Pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
Semin Nephrol Volume: 11 Page(s): 653 - 660
11/01/1991 Authors: Chapman AB; Schrier RW -
The renin-angiotensin system and polycystic kidney disease.
N Engl J Med Volume: 324 Page(s): 775 - 776
03/14/1991 Authors: del Castillo Caba D; Martin-Malo A; Perez Caldern R -
THE RENIN-ANGIOTENSIN SYSTEM AND POLYCYSTIC KIDNEY-DISEASE - REPLY
NEW ENGLAND JOURNAL OF MEDICINE Volume: 324 Page(s): 776 - 776
03/14/1991 Authors: CHAPMAN AB; JOHNSON AM; GABOW PA; SCHRIER RW -
LEFT-VENTRICULAR HYPERTROPHY OCCURS FREQUENTLY IN HYPERTENSIVE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE PATIENTS
Volume: 39 Page(s): A50 - A50
02/01/1991 Authors: CHAPMAN AB; HOSSACK K; JOHNSON AM; GABOW PA; SCHRIER RW -
Renal structure and hypertension in autosomal dominant polycystic kidney disease.
Kidney Int Volume: 38 Page(s): 1177 - 1180
12/01/1990 Authors: Gabow PA; Chapman AB; Johnson AM; Tangel DJ; Duley IT; Kaehny WD; Manco-Johnson M; Schrier RW -
The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
N Engl J Med Volume: 323 Page(s): 1091 - 1096
10/18/1990 Authors: Chapman AB; Johnson A; Gabow PA; Schrier RW -
Serum amylase in patients with renal insufficiency and renal failure.
Am J Gastroenterol Volume: 85 Page(s): 1377 - 1380
10/01/1990 Authors: Collen MJ; Ansher AF; Chapman AB; Mackow RC; Lewis JH -
Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease.
Am J Kidney Dis Volume: 16 Page(s): 252 - 255
09/01/1990 Authors: Chapman AB; Thickman D; Gabow PA -
FACTORS RELATING TO RENAL FUNCTIONAL DETERIORATION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD)
Volume: 37 Page(s): 248 - 248
01/01/1990 Authors: GABOW PA; JOHNSON AM; KAEHNY WD; CHAPMAN AB -
EVIDENCE FOR ROLE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) IN HYPERTENSION (HBP) OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD)
Volume: 37 Page(s): 397 - 397
01/01/1990 Authors: CHAPMAN AB; GABOW PA; JOHNSON AM; TSCHOPP M; SCHRIER RW -
PROSPECTIVE IMAGING STUDY OF ASYMPTOMATIC INTRACRANIAL ANEURYSMS IN POLYCYSTIC KIDNEY-DISEASE
Volume: 37 Page(s): 249 - 249
01/01/1990 Authors: KAEHNY WD; CHAPMAN AB; STEARS JC; GABOW PA; EARNEST MP -
VENOCONSTRICTION MAY EXPLAIN INCREASED PLASMA ATRIAL-NATRIURETIC-PEPTIDE (ANP) AND CARDIAC-OUTPUT (CO) IN HYPERTENSIVE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD)
Volume: 37 Page(s): 251 - 251
01/01/1990 Authors: SCHRIER RW; CHAPMAN AB; HIATT W; JOHNSON AM; TSCHOPP M; GABOW PA -
PROTEIN LOADING INDUCES MICROALBUMINURIA AND HYPOKALURIA IN TYPE-I DIABETIC SUBJECTS
Volume: 36 Page(s): S301 - S301
11/01/1989 Authors: CHAPMAN AB; WINCHESTER JF; EASTMAN R; DAWN K; RIZELL L; LYNAM L; BOYLE AS -
Effect of dietary constituents on renal function.
Kidney Int Suppl Volume: 27 Page(s): S68 - S72
11/01/1989 Authors: Winchester JF; Chapman AB -
PROTEIN LOADING (P) AND EXERCISE INDUCE MICROALBUMINURIA (MA) IN TYPE-I DIABETICS (DM) WITHOUT OVERT NEPHROPATHY (NE)
Volume: 35 Page(s): 440 - 440
01/01/1989 Authors: WINCHESTER JF; CHAPMAN AB; BOYLE AS; MULRONEY SE; RIZELL L; DAWN K; EASTMAN R -
Single kidney function: effect of acute protein and water loading on microalbuminuria.
Am J Med Volume: 85 Page(s): 752 - 754
11/01/1988 Authors: Chapman A; Boyle AS; Winchester JF -
ORAL PROTEIN LOADING INDUCES MICROALBUMINURIA IN TYPE-I DIABETICS WITHOUT PREVIOUS EVIDENCE OF NEPHROPATHY
Volume: 36 Page(s): A383 - A383
04/01/1988 Authors: CHAPMAN AB; WINCHESTER JF; EASTMAN R; LYNAM L -
Continuous arteriovenous hemofiltration in patients with severe congestive heart failure.
Am J Med Volume: 83 Page(s): 1167 - 1168
12/01/1987 Authors: Chapman A; Rotellar C; Mackow RC; Hanson K -
AMYLASE, LIPASE, ISOAMYLASE, AND TRYPSIN IN PATIENTS WITH RENAL-INSUFFICIENCY AND RENAL-FAILURE
Volume: 92 Page(s): 1296 - 1296
05/01/1987 Authors: ANSHER AF; COLLEN MJ; MACKOW RC; CHAPMAN AB; KORENMAN JC; CIARLEGLIO CA; BENJAMIN SB; RAKOWSKI TA -
Ultrastructure and function of cysts from human adult polycystic kidneys.
Kidney Int Volume: 17 Page(s): 372 - 381
03/01/1980 Authors: Cuppage FE; Huseman RA; Chapman A; Grantham JJ